**Core tip:** Accumulating evidence about circulating tumor cells and cell-free nucleic acids in the blood of cancer patients has suggested their potent clinical utilities as novel biomarker. This concept, so-called "liquid biopsy" is widely known as an alternative approach to cancer tissue biopsy. This method might facilitate a more sensitive diagnosis and better decision-making by obtaining genetic and epigenetic aberrations that are closely associated with cancer initiation and progression. In this article, we review recent developments based on the available literature on both circulating tumor cells and cell-free nucleic acids in cancer patients, especially focusing on Hepatocellular carcinoma.

INTRODUCTION
============

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide, but it ranks as the second most common cause of cancer-related death worldwide\[[@B1]\]. Despite recent development of a diagnostic and treatment method, the prognosis of HCC remains poor. Even in major advanced economies, the mortality rates have been increasing. Although HCC is a typical viral infection-related malignancy derived from chronic hepatitis B and C\[[@B2],[@B3]\], HCC has also been strongly associated with lifestyle. Excessive alcohol consumption, obesity, and type 2 diabetes are strongly associated with the carcinogenesis and development of HCC\[[@B4]-[@B7]\]. Both the proportion and number of HCC patients with non-viral etiologies have been increasing on a global scale. Therefore, defining the target population should be added to screening as the most important clinical issues.

Early screening of patients for HCC has been reported to confer a survival benefit\[[@B8],[@B9]\]. Patients who are identified early have multiple treatment options leading to improved outcomes. However, in clinical settings, only approximately 30% to 40% of patients with HCC can get effective treatment at the right time\[[@B10]\], and few molecules have been used as clinical biomarkers for HCC. Alpha-fetoprotein (AFP), AFP lectin fraction (AFP-L3), and des-γ-carboxy prothrombin (DCP, also known as proteins induced through vitamin K deficiency or antagonist-II, PIVKA-II) have been used as conventional serum tumor markers. However, these markers often show false-positive results, and lack sufficient sensitivity and specificity\[[@B11]-[@B13]\]. Therefore, to provide optimal treatment for each patient with HCC, more precise and effective biomarkers are urgently needed. Accumulating evidence of liquid biopsy might facilitate a more sensitive diagnosis and individualized decision-making in the duration of treatment of HCC.

In various cancers, many studies have demonstrated a large number of genetic and epigenetic aberrations contribute to carcinogenesis and their clinical utility\[[@B14]-[@B18]\]. Traditionally, these tumor-linked alterations has been provided from tissue samples of HCC patients. However, conventional procedures for tissue sampling from HCC patients is not always be conducted due to their clinical difficulties such as anatomical reasons, invasive nature, and/or the patient's poor hepatic status\[[@B19],[@B20]\]. Because of such backgrounds, conventional procedures have some problems: (1) Results from a single biopsy could provide considerably restricted information; and (2) they could not reflect current cancer status, such as treatment sensitivity and therapeutic efficiency. Detecting circulating tumor cells (CTCs) and/or circulating cell-free nucleic acids (cfNAs) in the blood of cancer patients could provide us a so-called "liquid biopsy", which would realize repeated samplings and reflecting the characteristics and dynamics of tumor\[[@B21]-[@B24]\].

To date, many study groups have revealed the possibility of CTCs and cfNAs in the blood, as blood-based biomarkers, for several types of cancers\[[@B21]-[@B24]\]. These novel biomarkers are thought to have great potential and could provide more detailed individualized decision-making during HCC treatment, including the following; risk assessment, early cancer detection, prediction of treatment or prognostic outcome. In this article, based on the available literature, we review the histological backgrounds, recent developments and prospects for the future of liquid biopsy, particularly focusing on Hepatocellular carcinoma.

BIOLOGY AND DETECTION OF CIRCULATING TUMOR CELLS
================================================

CTCs are generally recognized as the "seeds" of tumors, which are shed into peripheral blood from a tumor *in situ* and eventually establish metastatic tumors in other organs\[[@B20]\]. Therefore, theoretically, circulating tumor cells (CTCs) are useful markers for early diagnosis. In 1869, Ashworth initially demonstrated the presence of CTCs\[[@B25]\] in the blood of breast cancer patient. This patients has widespread breast cancer, and the cells similar to those in the primary breast cancer had been detected in her blood. Afterwards, to validate Ashworth's remarks, many researches have challenged to investigate peripheral blood of various cancer patients to identify CTCs.

However, the effort has been hampered by some difficulties. The problem is that the earlier the stage is, the less the cells are. Namely, the cell tends to be proportional to tumor volume. Moreover, CTCs have estimated infrequencies of approximately 1-10 CTCs in a background of millions of blood cells in patients with metastatic diseases\[[@B26]\]. In addition, less than 0.01% of CTCs introduced into the circulation survive to produce metastases. Furthermore, in phenotype, as well as genotype, CTCs are considered to be quite heterogeneous\[[@B27]-[@B29]\]. As CTCs are thought to be derived from the primary cancer or metastases, they are rarely present in patients with non-neoplastic disorders healthy person\[[@B30]\]. Therefore, the performance such as sensitivity and specificity of detection technique should be achieved to a proper level, precise detection of CTCs has been a major problem in this field for researchers.

TECHNIQUES FOR ISOLATION, ENRICHMENT, AND IDENTIFICATION OF CTCS
================================================================

In recent years, various CTC isolation and enrichment technologies have emerged, their approaches are generally categorized into two methods.

Physical methods
----------------

Physical methods mainly depend on the physical properties of CTCs, such as density, size, migratory capacity, deformability and electric charge\[[@B31]\]. Most CTCs originate from epithelial tumors are thought to larger than other blood cells, several filtration-based techniques has been developed\[[@B32],[@B33]\]. However, substantial difference has been demonstrated in cell size not only in an individual cancer patient but also in different cancer patients\[[@B34]-[@B36]\]. Thus, novel techniques adopting multiple filters have been studied to solve these issues and improve accuracy of enrichment of CTCs\[[@B37],[@B38]\]. These micro device could isolate cancer cells using their physical properties such as size continuously and deformability. For example, Mohamed et al\[[@B37]\] designed a micro-machined device, which had arrays of four successively narrower channels, were able to fractionate cancer cells without interference from the blood cells. Those novel techniques could have substantial possibilities, their utility should be validated in the future.

Biological methods
------------------

Another approach is biological methods, which mainly rely on antigen-antibody binding and antibodies against tumor-specific biomarkers including epithelial cell adhesion molecule (EpCAM), human epidermal growth factor receptor2 (Her2), and prostate-specific antigen (PSA) that are typically used in CTCs purification\[[@B39]\]. Currently, Cell-Search^TM^ (Veridex LLC, NJ, United States) is the most commonly used CTC platform. In this platform, immunomagnetic beads coated with EpCAM antibodies capture CTCs, followed by immunostaining with two positive markers, which are cytokeratins 8/18/19 for cytoplasmic epithelium and 4′,6′-diamidino-2-phenylindole hydrochloride for nucleic acids, and a negative marker, leukocyte-specific CD45. Its utility as a clinical indicator has been shown in the patients with metastatic breast, prostate, and colon cancers\[[@B40]-[@B45]\]. Therefore, this system has been the only CTC platform to be approved by the United States Food and Drug Administration. However, it could not capture CTCs that have increased the malignant potential, caused by the acquisition of an epithelial-mesenchymal transition (EMT). Concerning the detection and isolation capability and the clinical utility of CTCs, many challenges remain. To overcome its insufficient capability and accuracy, advanced technologies have emerged. "CTC-chip" is the representative technology without being influenced by the heterogeneity of them. It is a unique microfluidic platform, capable of efficient and selective separation of viable CTCs from peripheral whole blood samples, mediated by the interaction of target CTCs with antibody (EpCAM)-coated microposts\[[@B46]\]. Most recently, CTC-Chip was reported to detect CTCs with high accuracy by using tumor-specific markers, such as human epidermal growth factor (HER2) in breast cancer or prostate-specific antigen (PSA) in prostate cancer, in addition to epithelial markers\[[@B46],[@B47]\]. Another unique approach was reported by Saucedo-Zeni et al\[[@B48]\] They captured and enriched CTCs from medical Seldinger guidewire, which were inserted into cubital veins. Despite these advances, the methodology of isolation and enrichment of CTCs has been in the process of development.

The identification process is generally conducted after the isolation and enrichment process. To identify genetic aberrations and other biological characteristics of CTCs, several methodologies, such as immunocytochemistry and molecular techniques, have been used. Conventionally, immunostaining using 4′,6′-diamidino-2-phenylindole hydrochloride as a nuclear stain, CK as an epithelial marker, and CD45 as a hematopoietic marker has been commonly adopted\[[@B49]\]. In various molecular approaches, quantitative reverse transcription-polymerase chain reaction (RT-PCR) has been widely used to identify the molecular characteristics of CKs, CEA, and other markers\[[@B50]\].

CTC DETECTION AND ITS CLINICAL RELEVANCE IN HCC PATIENTS
========================================================

In the past decades, CTCs in HCC patients have been intensively studied. Table [1](#T1){ref-type="table"} is the summary of previously demonstrated candidates. As described in the last paragraph, these approaches are generally categorized into two methods: physical and biological methods.

###### 

Circulating tumor cells in hepatocellular carcinoma

  **Ref**.                           **HCC patients**         **Ethnicity**     **Background liver status**   **Patient background**                                                                          **Controls**                     **Methodology**                    **Positive rate**
  ---------------------------------- ------------------------ ----------------- ----------------------------- ----------------------------------------------------------------------------------------------- -------------------------------- ---------------------------------- ---------------------
  Matsumura, et al\[[@B51]\], 1999   88                       Japan             HCV: 85%, HBV: 6%             Pre and post (TAE or PEI)                                                                       NA                               RT-PCR (AFP)                       63.0%
  Mou et al\[[@B56]\], 2002          30                       China             HBV: 100%                     Pre resection                                                                                   25 (HV: 25)                      RT-PCR (MAGE1/3)                   43.3%
  LC: 100%                                                                                                                                                                                                                                                                        
  Witzigmann et al\[[@B55]\], 2002   85                       Germany           NA                            Pre, during, post (Resection: 24, LT: 10, TACE: 13, No treatment: 38)                           116 ( OLT: 50, HD: 39, HV: 27)   RT-PCR (AFP)                       28.0%
  Vona et al\[[@B31]\], 2004         44                       France            LC: 89%                       Pre/post resection: 22                                                                          107 (HV: 38, HD: 69)             ISET                               52.2%
  Unresectable: 22                                                                                                                                                                                                                                                                
  Jeng et al\[[@B53]\], 2004         81                       China             HBV: 77%, HCV: 38%            Pre and post resection                                                                          50 (HV: 30, HD: 20)              RT-PCR (AFP)                       23.4%
  LC: 69%                                                                                                                                                                                                                                                                         
  Cillo et al\[[@B52]\], 2004        50                       Italy             HCV: 50%,HBV: 12%             Pre (Resection: 17, LT: 9, PT: 17)                                                              50 (HD: 6, OT: 44)               RT-PCR (AFP)                       40.0%
  HCV and HBV: 6%                                                                                                                                                                                                                                                                 
  Alcohol: 10%                       No treatment: 7                                                                                                                                                                                                                              
  LC: 84%                                                                                                                                                                                                                                                                         
  Kong et al\[[@B59]\], 2009         343                      South Korea       HBV: 78%, HCV: 10%            Pre (Resection: 12, TACE: 224, RFA: 44, Chemotherapy: 12, Radiotherapy: 12, No treatment: 39)   NA                               RT-PCR (AFP)                       
  Alcohol: 6%                        (hTERT)                  59.5%                                                                                                                                                                                                               
  LC: 52%                            14.0%                                                                                                                                                                                                                                        
  Fan et al\[[@B69]\], 2011          82                       China             HBV: 80%                      Pre and post resection                                                                          NA                               CellSearch^TM^                     68.3%
  Xu et al\[[@B70]\], 2011           85                       China             HBV: 84%, HCV: 7%             Pre Resection: 63                                                                               71 (HD: 37, HV: 20, OT: 14)      CellSearch^TM^                     81.0%
  HBV and HCV: 5%                    Clinical Diagnosis: 22                                                                                                                                                                                                                       
  nonB, nonC: 4%                                                                                                                                                                                                                                                                  
  Liu et al\[[@B67]\], 2013          60                       China             HBV: 93%                      Pre resection                                                                                   NA                               Flow cytometry                     50.0%
  LC: 93%                                                                                                                                                                                                                                                                         
  Yao et al\[[@B57]\], 2013          123                      China             HBV: 72%                      NA                                                                                              276 (HV: 30, HD: 196, OT: 50)    RT-PCR (GPC-3)                     70.77%
  LC: 93%                                                                                                                                                                                                                                                                         
  Sun et al\[[@B73]\], 2013          123                      China             HBV: 75%                      Pre/post resection                                                                              NA                               CellSearch^TM^                     66.6%
  LC: 76%                                                                                                                                                                                                                                                                         
  Schulze et al\[[@B72]\], 2013      59                       Germany           Alcohol: 38%                  Pre (resection or systemic therapy)                                                             19 (HD: 19)                      CellSearch^TM^                     30.5%
  HBV: 17%, HCV: 13%                                                                                                                                                                                                                                                              
  LC: 89%                                                                                                                                                                                                                                                                         
  Li et al\[[@B71]\], 2013           60                       China             HBV: 92%, HCV: 3%             NA                                                                                              30 (HD: 10, HV: 10, OT: 10)      CellSearch^TM^                     76.6%
  nonB, nonC: 7%                                                                                                                                                                                                                                                                  
  LC: 88.7%                                                                                                                                                                                                                                                                       
  Bahnassy et al\[[@B68]\], 2014     70                       Egypt             HCV: 100%                     NA                                                                                              63 (HD: 30, HV: 33)              Flow cytometry (CK19, CD90, 133)   73.0%, 49.8%, 69.5%
  RT-PCR (Telomerase, MAGE1/3)       55.7%, 60.0%, 62.9%                                                                                                                                                                                                                          
  Li et al\[[@B76]\], 2014           27                       China             NA                            NA                                                                                              61 (HD: 34, HV: 15, OT: 12)      CellSearch^TM^                     88.9%
  Mu et al\[[@B78]\], 2014           62                       China             HBV: 95.2%                    NA                                                                                              22 (HD: 7, HV: 15)               CellSearch^TM^                     48.3%
  Fang et al\[[@B74]\], 2014         42                       China             LC: 55%                       Pre and post TACE                                                                               20 (HV: 10, HD: 10)              CellSearch^TM^                     52.3%
  Morris et al\[[@B77]\], 2014       52                       United Kingdom    Alcohol: 38%,                 No treatment                                                                                    NA                               CellSearch^TM^                     28%
  HBV: 8%                            ISET                     100%                                                                                                                                                                                                                
  Diabetes: 12%                                                                                                                                                                                                                                                                   
  Guo et al\[[@B75]\], 2014          299                      China             HBV: 90%                      Pre/post (Resection: 157, TACE: 76, RFA: 66)                                                    120 (HV: 71, HD: 25, BT: 24)     CellSearch^TM^                     42.6%
  LC: 90%                                                                                                                                                                                                                                                                         
  Choi et al\[[@B58]\], 2015         81                       South Korea       HBV: 80%, HCV: 11%            Pre and post (Resection: 64, LT: 17)                                                            16 (LHD: 16)                     RT-PCR (K19, CD44)                 22.2%
  Alcohol: 4%                                                                                                                                                                                                                                                                     
  LC: 59%                                                                                                                                                                                                                                                                         
  Kelley et al\[[@B19]\], 2015       20                       Caucasian: 55%,   HBV: 25%, HCV: 45%            NA                                                                                              10 (HD: 10)                      CellSearch^TM^                     40.0%
  Asian: 35%,                        HBV and HCV: 10%                                                                                                                                                                                                                             
  American: 10%                      Alcohol: 5%                                                                                                                                                                                                                                  
  (African-5%)                       NAFLD: 10%                                                                                                                                                                                                                                   
  (Native-5%)                                                                                                                                                                                                                                                                     
  Wang et al\[[@B79]\], 2016         42                       China             HBV: 81%, HCV: 2%             NA                                                                                              NA                               CTC-Chip                           59.5%
  nonB, nonC: 17%                                                                                                                                                                                                                                                                 
  Zhang et al\[[@B207]\], 2016       36                       China             NA                            NA                                                                                              NA                               CTC-Chip                           100%

NA: Not applicable; LC: Liver cirrhosis; NAFLD: Non-alcoholic fatty liver disease; TAE: Trans-arterial embolization; PEI: Percutaneous ethanol injection; LT: Liver transplantation; TACE: Trans-catheter arterial chemoembolization; RFA: Radiofrequency ablation; PT: Percutaneous treatment; HV: Healthy volunteers; HD: Hepatic disease without evidence of HCC; OLT: Other malignant liver tumors; BT: Benign tumor; OT: Other cancerous disease; LHD: Liver healthy donors; RT-PCR: Reverse transcriptase polymerase chain reaction; ISET: Isolation by size of epithelial tumor cells.

Physical methods
----------------

Vona et al\[[@B31]\] first reported the isolation by size of epithelial tumor cell (ISET) method to detect CTCs in HCC patients. By cytomorphologic analysis, they demonstrated that the spontaneous circulation of CTCs in peripheral blood reflects tumor progression and tumor spread in patients with HCC. Compared with expensive and cumbersome molecular techniques, ISET is a unique, inexpensive methodology. In this method, we can apply the cytopathological diagnosis of tumor cells, which were widely used in clinical oncology, as peripheral blood samples without any special equipment\[[@B32]\]. However, ISET device is still hard to release CTCs from the membrane. This may limit the application of downstream genetic analysis.

Biological methods
------------------

The presence and clinical utility of CTCs in HCC was first reported by Matsumura et al\[[@B51]\] using RT-PCR. They demonstrated the following. (1) the presence of alpha-fetoprotein (AFP) messenger RNA (mRNA) in peripheral blood could be a marker of circulating HCC cells; (2) the status of AFP mRNA in blood were investigated at entry, extrahepatic metastasis developed more frequently among the AFP mRNA-positive patients than among the AFP mRNA-negative patients; and (3) after treatment, AFP mRNA was investigated, and cumulative metastasis-free survival and overall survival were significantly better in patients whose AFP mRNA became negative after treatment than in patients with persistently positive AFP mRNA. In summary, they demonstrated that the presence or absence of AFP mRNA in blood (CTCs' positivity) could be a predictor of outcome in patients with HCC.

Following this study, the clinical utility of peripheral AFP mRNA was validated by other groups\[[@B52],[@B53]\]; however, the significance as prognostic marker has not been adequately confirmed\[[@B54],[@B55]\]. Thus, other tumor-specific molecules in the bloodstream, such as MAGE-1, MAGE3\[[@B56]\], glypican-3 (GPC-3)\[[@B57]\], keratin 19 (K19), cluster of differentiation 44 (CD44)\[[@B58]\], and hTERT\[[@B59]\] mRNA, have been investigated for markers of circulating HCC cells. For example, MAGE gene transcripts have been considered as HCC-specific markers\[[@B60]\]. Mou et al\[[@B56]\] demonstrated that detection of MAGE transcripts in blood with a follow-up survey could predict the prognosis and monitor the response to therapy. GPC-3 is a membrane-anchored heparin sulfate proteoglycan, known to be a reliable biomarker for HCC\[[@B61]\]. Yao et al\[[@B57]\] demonstrated that GPC-3 mRNA abnormality is useful as clinical biomarkers from early cancer detection to evaluating metastasis. Furthermore, K19 and CD44 have been shown to be cancer stem cell markers in HCC\[[@B62]-[@B65]\], their significance of prognostic factor in peripheral blood were also demonstrated by Choi et al\[[@B58]\]. However, HCC associated genes were not always candidates for the markers of CTCs. Although serum human telomerase reverse transcriptase protein (hTERT) mRNA expression has been suggested as a potential candidate diagnostic marker for HCC\[[@B66]\], the significance as prognostic marker has not been adequately confirmed\[[@B59]\].

Liu e*t al*\[[@B67]\] and Bahnassy et al\[[@B68]\] used flow cytometry to analyze intercellular adhesion molecule 1 (ICAM-1) expression, cytokeratin 19, CD133, and CD90 in HCC blood samples and demonstrated their prognostic value. Among various techniques, EpCAM-based Cell-Search^TM^ is currently the most widely used CTC platform\[[@B19],[@B69]-[@B78]\]. Using this method, Sun et al\[[@B73]\] collected blood samples from 123 HCC patients who underwent curative resection and suggested that EpCAM^+^ CTCs could be useful for real-time parameter for monitoring treatment response and be also used for therapeutic target in HCC recurrence. Guo et al\[[@B75]\] collected blood samples from 299 HCC patients with various kinds of treatment and 120 control subjects, and demonstrated that this method could be useful in early decision-making to tailor the most effective antitumor strategies. Most recently, Wang et al\[[@B79]\] suggested that novel CTC-Chip platform might be a new method for a simple and efficient detection of CTCs in HCC patients. They created biocompatible and transparent Hydroxyapatite/chitosan nanofilm coated by aptamer for carbohydrate sialyl Lewis Xto and demonstrated that it could be useful as prognostic marker.

Overall, the usefulness of CTCs as biomarkers in HCC might be practically guaranteed. However, several challenges that must be overcome remain. Firstly, it is possible that etiological differences of patients and controls, such as background liver disease, haptic status, and race, could be responsible for the heterogeneity of the results. Secondly, a novel methodology for the detection should be provided for solving the problem of the rarity and heterogeneity of CTCs. Thirdly, the techniques and results of past research have greatly differed. Consequently, a large-scale validation using patients with homogeneous backgrounds and development of a unified methodology are required for future applications.

BIOLOGY AND DETECTION OF CELL-FREE NUCLEIC ACIDS
================================================

cfNAs in peripheral blood of cancer patients, comprised of DNA, mRNA, and miRNA, are known to come from apoptotic and necrotic cells or are released from living eukaryotic cells\[[@B21]\]. The first discovery of cfNAs in human peripheral blood was in 1948 by Mandel and Metais\[[@B80]\]. However, their work did not gain attention for a long time due to insufficient understanding of that new concept, completely different from conventional ones. Cell free DNAs were first discovered by Leon et al\[[@B81]\] in the serum of cancer patients in 1977. They also suggested it could be a clinical indicator of treatment outcome, showing decreased cfDNA levels in response to radiotherapy. Since then, numerous alterations in cfNAs have been demonstrated in various cancer patients. Cell free DNA with cancer characteristics was first discovered by Vasioukhin et al\[[@B82]\] in 1989. Tumours can shed DNA into the circulation. Their discovery indicated the possibility that cancers could release DNA into the blood of the cancer patients. This hypothesis was validated in the plasma of cancer patients: *KRAS* mutation in the pancreatic cancer patients\[[@B83]\] and *NRAS* mutation in the leukemia patients\[[@B84]\].

The state of RNA in the blood is easy-to degrade by the presence of endogenous ribonuclease, however, cell-free RNA has been demonstrated in blood. The presence of cfRNA was first discovered in 1999 from the serum of patients with nasopharyngeal carcinoma\[[@B85]\] and malignant melanoma\[[@B86]\]. Afterwards, many study group have demonstrated the presence and utility of mRNA in the blood of various cancer patients\[[@B87]-[@B89]\].

In 2008, Mitchell et al\[[@B90]\] first demonstrated that circulating microRNAs (miRNAs) in patients with solid cancers could be a promising biomarker. Since then, circulating noncoding RNAs have been intensively studied. Among them, miRNAs has especially gained attention. Other noncoding RNAs, such as small nucleolar RNA (snoRNA), small nuclear RNA (snRNA), piwi-interacting RNA (piRNA), and long noncoding RNA (lncRNA), have been also expected to be biomarkers, however, there are few studies of these. In the future, further research will probably be necessary.

CIRCULATING CELL-FREE DNA DETECTION AND ITS CLINICAL RELEVANCE IN HCC PATIENTS
==============================================================================

Circulating cfDNA, a naturally occurring biological material, is generally considered to be a potential novel biomarker for a long time\[[@B91]\]. These abnormalities can be divided into two changes, such as quantitative changes and qualitative changes. Quantitative changes appear as higher concentrations of total circulating cfDNA, qualitative changes are gene mutations, DNA copy number variations, tumor-specific methylation, microsatellite instability (MSI) and loss of heterozygosity. Thus, analysis of circulating cell-free DNA in the plasma/serum can be mainly categorized into two strategies. One of these strategies is to measure the quantity of cell-free DNA in circulation. The other strategy is to detect tumor-specific genetic aberrations. Most researchers have adopted studies the later one as liquid biopsy\[[@B92]-[@B95]\].

Table [2](#T2){ref-type="table"} is the summary of previously demonstrated candidates. Some researchers have adopted a quantitative analysis\[[@B96]-[@B102]\]. Huang et al\[[@B100]\] and Chen et al\[[@B99]\] demonstrated that plasma DNA or serum DNA levels were significantly higher in HCC patients and they were associated with a poorer prognosis; however, it has not become a mainstream of cfDNA studies because the elevated levels of cfDNA were not specific for HCC. Although single nucleotide mutation\[[@B103]\] and copy number variation\[[@B95],[@B104]\] were representative changes for the qualitative strategy, the "methylation pattern" has been the most intensively investigated. Initially, the presence and the clinical utility of circulating cell-free DNA in HCC was reported by Wong et al\[[@B105]\]. Using methylation-specific PCR, they analyzed p15 methylation patterns in three kinds of samples such as plasma, serum, and tissues surgically resected from HCC patients and showed the following: (1) in the blood samples, methylated p15 sequences were detected in 25% of patients with p15 methylation in the tissue; (2) nearly all patients showing p15 and p16 methylation in the tissue had detectable methylation abnormalities in their blood samples; and (3) clinical metastasis or recurrence were developed in the patients with p15/p16 methylation. In summary, these epigenetic markers could serve as diagnostic and prognostic markers. As previous studies revealed that changes of DNA methylation exited in various malignancies and played an important role in carcinogenesis\[[@B106],[@B107]\], following this study, many researchers investigated the cfDNA methylation profile in HCC patients\[[@B108]-[@B124]\]. For example, Iyer et al\[[@B115]\] compared the tumor methylation profile for tumor suppressor genes, such as APC, FHIT, p15, p16, and E-cadherin, and in tumor tissues and plasma from the same HCC patients, and demonstrated that concordance between the two types of specimens was statistically significant for all five genes. It suggested that plasma DNA reliably predicts methylation events in tissue DNA; therefore, plasma DNA could be used for methylation studies. Huang et al\[[@B116]\] analyzed the plasma methylation status of four genes (APC, GSTP1, RASSF1A, and SFRP1) and showed the sufficient diagnostic value of cfDNAs. Although the area under the receiver-operation characteristic curve (AUC-ROC) for an individual gene was not adequate, the combination analysis of these four genes indicated higher AUC (0.933) in discriminating HCC from the normal control. Furthermore, they demonstrated methylated RASSF1A in plasma could be an independent prognostic factor for overall survival.

###### 

Circulating cell-free DNA in hepatocellular carcinoma

  **Ref**                                    **HCC patients**    **Sample**               **Ethnicity**         **Background liver**   **Controls**            **cfDNA abnormalities**      **Target**
  ------------------------------------------ ------------------- ------------------------ --------------------- ---------------------- ----------------------- ---------------------------- --------------------------------------
  Wong et al\[[@B105]\], 2000                25                  Plasma/serum             Hong-Kong             HBV: 88%               55 (HD: 35, HV: 20)     Methylation                  P16
  15                                         Buffy coat          HCV: 2%                  35 (HD: 15, HV: 20)   MS-PCR                                                                      
  Wong et al\[[@B108]\], 2003                29/22               Plasma/serum             Hong Kong             NA                     50 (HD and HV)          Methylation                  P16INK4A
  29                                         Buffy coat          35 (HD: 15, HV: 20)      MS-PCR                                                                                            
  Chu et al\[[@B109]\], 2004                 46                  Serum                    Korea                 HBV: 65%               23 (HD: 23)             Methylation                  P16INK4A
  HCV: 22%                                   MS-PCR                                                                                                                                         
  Yeo et al\[[@B110]\], 2005                 40                  Plasma                   Hong-Kong             HBV: 83%               10 (HV: 10)             Methylation                  RASSF1A
  MS-PCR                                                                                                                                                                                    
  Iizuka et al\[[@B96]\], 2006               52                  Serum                    Japan                 HCV: 100%              46 (HD: 30, HV: 16)     Quantitative analysis        GSTP1
  Real-time PCR                                                                                                                                                                             
  Ren et al\[[@B97]\], 2006                  79                  Plasma                   China                 HBV: 85% LC: 86%       40 (HD: 20, HV: 20)     Quantitative analysis        NA
  Real-time PCR                                                                                                                                                                             
  Allelic imbalance analysis                 D8S258 and D8S264                                                                                                                              
  Zhang et al\[[@B112]\], 2007               50                  Serum                    Taiwan                HBV: 22%               50                      Methylation                  P15, P16
  HCV: 16%                                   HV: 50              MS-PCR                                                                                                                     
  Tan et al\[[@B111]\], 2007                 8                   Serum                    Singapore             NA                     72 (OT: 62, HV: 10)     Methylation                  RUNX3
  MS-PCR                                                                                                                                                                                    
  Chan et al\[[@B113]\], 2008                85                  Serum                    Hong-Kong             HBV: 92%               135 (HD: 63, HV: 72)    Methylation                  RASSFIA
  RT-PCR                                                                                                                                                                                    
  Chang et al\[[@B114]\], 2008               19                  Plasma                   China                 HBV: 89%               17 (LC: 17)             Methylation                  APC, GSTP1, RASSF1A, P16, E-cadherin
  MS-PCR                                                                                                                                                                                    
  Iyer et al\[[@B115]\], 2010                28                  Plasma                   Egypt                 HCV: 79%               NA                      Methylation                  APC, FHIT, P15, P16 and E-cadherin
  HNV: 18%                                   MS-PCR                                                                                                                                         
  Yang et al\[[@B98]\], 2011                 60                  Plasma                   China                 NA                     50 (HD: 21, HV: 29)     Quantitative analysis        hTERT
  FQ-PCR                                                                                                                                                                                    
  Szymañska et al\[[@B103]\], 2011           14                  Plasma                   China                 Mostly HBV             NA                      Single nucleotide mutation   R249S (TP53 mutation)
  SOMA                                                                                                                                                                                      
  Iizuka et al\[[@B117]\], 2011              220                 Serum                    Japan                 HCV: 100%              202 (HD: 202)           Methylation                  SPINT2, SRD5A2
  MS-PCR                                                                                                                                                                                    
  Huang et al\[[@B116]\], 2011               72                  Plasma                   China                 HBV: 85%               37 (HD: 37)             Methylation                  APC, GSTP1, RASSF1A, and SFRP1
  MSRE-qPCR                                                                                                                                                                                 
  Huang et al\[[@B100]\], 2012               72                  Plasma                   China                 HBV: 85%               115 (HD: 74, HV: 41)    Quantitative analysis        NA
  Real-time PCR                                                                                                                                                                             
  Chen et al\[[@B99]\], 2012                 80                  Serum                    China                 HBV: 100%              130 (HD: 80, HV: 50)    Quantitative analysis        NA
  Real-time PCR                                                                                                                                                                             
  Mohamed et al\[[@B118]\], 2012             40                  Serum                    Egypt                 HCV: 100%              60 (HD: 40, HV: 20)     Methylation                  RASSF1A
  Real-time PCR                                                                                                                                                                             
  Chen et al\[[@B101]\], 2013                39                  Serum                    China                 HBV: 79%               45 (HV: 45)             Quantitative analysis        NA
  Real-time PCR                                                                                                                                                                             
  Piciocchi et al\[[@B102]\], 2013           66                  Plasma                   Italy                 HCV: 51%               76 (HD: 76)             Quantitative analysis        hTERT
  Alcohol: 27%                               Real-time PCR                                                                                                                                  
  Chan et al\[[@B95]\], 2013                 4                   Plasma                   China                 NA                     20 (HD: 4, HV: 16)      Copy number variation        NA
  MPS                                                                                                                                                                                       
  Sun et al\[[@B119]\], 2013                 43                  Serum                    China                 HBV: 86%               50 (HD: 24, HV: 26)     Methylation                  TFPI2
  MS-PCR                                                                                                                                                                                    
  Zhang et al\[[@B120]\], 2013               37                  Serum                    China                 HBV: 100%              33 (HD: 33)             Methylation                  DBX2, THY1
  Bead Chip, Hot-start PCR, Pyrosequencing                                                                                                                                                  
  Huang et al\[[@B122]\], 2014               66                  Serum                    United States         HCV: 100%              43 (HD: 43)             Methylation                  INK4A
  HCV and HBV: 6%                                                Pyrosequencing, MS-PCR                                                                                                     
  Han et al\[[@B121]\], 2014                 160                 Serum                    China                 HBV: 22%               133 (HD: 88, HV: 45)    Methylation                  TRG5
  MS-PCR                                                                                                                                                                                    
  Ji et al\[[@B123]\], 2014                  121                 Serum                    China                 HBV: 83%               68 (HD: 37, HV: 31)     Methylation                  MT1M
  MS-PCR                                                                                                                                                                                    
  Kuo et al\[[@B124]\], 2014                 40                  Plasma                   Taiwan                NA                     34                      Methylation                  HOXA9
  MS-PCR                                                                                                                                                                                    
  Jiang et al\[[@B104]\], 2015               90                  Plasma                   Hong-Kong             NA                     135 (HD: 103, HV: 32)   Copy number variation        NA
  CAZA                                                                                                                                                                                      

NA: Not applicable; HD: Hepatic disease without evidence of HCC; HV: Healthy volunteers; RT-PCR: Reverse transcriptase polymerase chain reaction; SOMA: Short oligonucleotide mass analysis; CAZA: Chromosome arm-level z-score analysis; MPS: Massively parallel sequencing; MS-PCR: Methylation-specific PCR; RT-PCR: Real time polymerase chain reaction; MSRE-qPCR: Methylation-sensitive restriction enzymes-based quantitative PCR; FQ-PCR: Real-time quantitative fluorescent polymerase chain reaction.

MS-PCR has been widely used for methylation research, because it provides a rapid and simple method with high sensitivity and accuracy. More recently, droplet digital PCR\[[@B125]-[@B128]\] and genome-wide high-throughput sequencing\[[@B128],[@B129]\] has been reported as a further accurately detection tools for rare and multiple types of mutations in circulating DNA. These novel approaches has revealed that genetic aberrations in cell-free DNA gained from the bloodstream of cancer patients and drug resistance were correlating\[[@B130]-[@B132]\]. It is required that the potent clinical utility of cell-free DNA, such as risk assessment, early cancer detection, prediction of drug resistance and prognostic outcome, could be demonstrated in the patients with HCC.

CIRCULATING CELL-FREE MRNA IN PLASMA/SERUM AND HCC
==================================================

Although RNA is fragile, easily degraded by ribonuclease (RNase) and the concentration of RNase in plasma/serum is known to be elevated in cancer patients\[[@B133]\], many researchers have successfully demonstrated the stable presence of cell-free mRNAs in the bloodstream of cancer patients. Recently, novel mechanistic insights have been gained that these RNAs can be incorporated into other surrounding such as exosomes, microvesicles and multivesicles, which considered to be sufficiently protected from the degradation by RNases and released from the cellular surface to the blood\[[@B134]\]. There are many studies of cell-free mRNA in the blood of patients with various solid cancers, and most of them targeted the mRNAs in plasma/serum whose up-regulation were previously validated in cancer tissues\[[@B87]-[@B89],[@B135]-[@B137]\]. Regarding HCC, several study groups investigate mRNA in peripheral blood mononuclear cells as a marker for the detection of CTCs\[[@B51]-[@B53],[@B55]-[@B57],[@B59]\]; however, the quantity of cell-free mRNAs in plasma/serum is exceedingly small. Further studies of cell-free mRNA in patients with HCC may provide new knowledge to the research field of liquid biopsy.

CIRCULATING NONCODING RNA IN PLASMA/SERUM
=========================================

Although as much as 80% of genomic DNA had already demonstrated to be transcribed into RNAs\[[@B138]\], the Human Genome Project revealed that the open reading frames of protein genes is only 2% of the 3.2 billion bases\[[@B139],[@B140]\]. It can be paraphrased as there are only a very few human genomic DNAs that actually code proteins. It is gradually reveled that various noncoding RNAs (ncRNAs) play crucial roles in several cellular processes in the transition from DNA to protein. Therefore, the expression patterns of ncRNAs could be promising molecular biomarkers in novel diagnostic techniques\[[@B141]\].

For circulating ncRNAs, particular attention has been paid to miRNAs. MiRNAs are small non-coding RNAs that play crucial roles in various cellular processes. A single miRNA could regulate the expression of genes as follows: A guide strand of mature miRNA is taken into the RNA-induced silencing complex and then hybridizes to the 3′-untranslated region of their target mRNAs to translate or degrade these mRNAs. Thus, miRNAs have occupied important place in all cellular processes, some alterations in miRNA expression has come to draw a lot of attention in the association with various disease. Particularly, some researchers have demonstrated that specific miRNAs could act like oncogenes or tumor suppressors. Several studies in recent years on this subject have also shown that some extracellular miRNAs were generated from both cell lysis and active secretion\[[@B21],[@B142],[@B143]\]. Furthermore, several researchers have detected miRNAs in the plasma/serum in a remarkably stable form. In this regard, Kosaka et al\[[@B143]\] proved that secretory mechanisms and intercellular transfer of microRNAs in living cells. A group of miRNAs is packaged into small membrane vesicles called exosomes and released through a ceramide-dependent secretory machinery. Furthermore, miRNAs are remarkably stable form in plasma as they bind to certain proteins, such as argonaute 2 and high-density lipoproteins\[[@B144]\]. Therefore, all circulating miRNAs, regardless of whether they are taken into certain protein complexes and/or cell-derived microvesicles, has been thought to be sufficiently protected against the degradation by RNases in the bloodstream. These findings of recent years have pioneered a novel research field in cancer science.

In 2008, Mitchell et al\[[@B90]\] first reported that circulating miRNAs could be useful for stable blood-based markers for cancer detection. Since then, circulating miRNAs in the blood of cancer patients have been intensively studied to validate their potential as biomarkers. Table [3](#T3){ref-type="table"} is the summary of previously demonstrated candidates. In 2010, Li et al\[[@B145]\] first demonstrated that serum miRNAs expression profile could be useful as novel noninvasive biomarkers for the distinction between HBV infection and HBV-positive HCC. Since then, several research groups have reported the potential utility of miRNAs circulating in plasma/serum in clinical applications. Concerning circulating miRNAs in HCC, more than 70 miRNAs have been thought to be useful for biomarkers\[[@B145]-[@B195]\]. Some miRNAs had been used in combination with AFP, conventional serum tumor marker, to improve diagnostic accuracy\[[@B158],[@B171],[@B177],[@B188],[@B191],[@B195]\]. Moreover, one miRNA could influence various mRNAs, more and more miRNAs and related mRNAs continues to be reported by numerous research groups. However, they are not always superimposable due to the large variances in the results. Thus, to realize more accurate diagnosing, some researchers have tried to use miRNAs in combination. Zhou et al\[[@B150]\] using the unique panel consisting of 7 mRNAs (miR-122, -192, -21, -223, -26a, -27a, and -801), based on the expression in plasma, could differentiate HCC from healthy (AUC = 0.941), chronic hepatitis B (AUC = 0.842), and cirrhosis (AUC = 0.884). More recently, Tan et al\[[@B166]\] reported that a combination of eight miRNAs could provide high diagnostic accuracy for HCC.

###### 

Circulating cell-free microRNA in hepatocellular carcinoma

  **miR**       **Expression**   **Sample**                         **HCC patients**        **Ethnicity**           **Background liver**               **Controls**                   **Value**                        **Ref**.
  ------------- ---------------- ---------------------------------- ----------------------- ----------------------- ---------------------------------- ------------------------------ -------------------------------- -------------------------------
  miR-1         Up               Serum                              195                     Germany                 HCV: 45%, Alcohol: 33%, HBV: 17%   54 (HD: 54)                    P                                Köberle et al\[[@B155]\] 2013
  miR-10b       Up               Blood                              27                      China                   Alcohol: 23%                       81 (HD: 81)                    D                                Jiang et al\[[@B175]\] 2015
  miR-15b       Up               Serum                              153                     China                   HBV: 88%                           59 (HD: 29, HV: 39)            D                                Liu et al\[[@B152]\] 2012
  miR-15b-5p    Down             Plasma                             37                      China                   NA                                 60 (HD: 29, HV: 31)            D                                Chen et al\[[@B170]\] 2015
  miR-16        Down             Serum                              105                     United States           HCV: 64%, HBV: 20%                 178 (HD: 107, HV: 7)           D                                Qu et al\[[@B148]\] 2011
  90            China            NA                                 60 (HV: 60)             D                       Ge et al\[[@B161]\] 2014                                                                           
  40            Egypt            HCV: 100%                          60 (HD: 40, HV: 20)     D                       El-Abd et al\[[@B174]\] 2015                                                                       
  miR-17-5p     Up               Serum                              136                     China                   NA                                 NA                             P                                Zheng et al\[[@B159]\] 2013
  8             Turkey           HCV: 100%                          84 (HD: 56, HV: 28)     D                       Oksuz et al\[[@B178]\] 2015                                                                        
  miR-18a       Up               Serum                              101                     China                   HBV: 100%                          90 (HD: 30, HV: 60)            D                                Li et al\[[@B151]\] 2012
  Up            Serum            20                                 South Korea             HBV: 70%                40 (HD: 40)                        D                              Sohn et al\[[@B179]\] 2015       
  miR-19a       Down             Serum                              112                     Egypt                   HCV: 100%                          167 (HD: 125, HV: 42)          D                                Motawi et al\[[@B177]\] 2015
  miR-21        Up               Plasma                             457                     China                   HBV:100%                           477 (HD: 310, HV: 167)         D                                Zhou et al\[[@B150]\] 2011
  136           Japan            HCV:68%, HBV: 23%                  80 (HD: 30, HV: 50)     D, P                    Tomimaru et al\[[@B153]\] 2012                                                                     
                Serum            101                                China                   HBV: 75%                137 (HD: 48, HV: 89)               D                              Xu et al\[[@B149]\] 2011         
  136           China            HBV: 95%                           NA                      P                       Liu et al\[[@B164]\] 2014                                                                          
  97            China            HBV: 62%                           30 (HV: 30)             D, P                    Wang et al\[[@B180]\] 2015                                                                         
  23            Egypt            HCV: 87%, HBV: 13%                 17 (HD: 17)             D                       Amr et al\[[@B186]\] 2016                                                                          
  Down          Serum            70                                 China                   HBV: 100%               72 (HD 48, HV: 24)                 D                              Qi et al\[[@B147]\] 2011         
  90            China            NA                                 60 (HV: 60)             D, P                    Ge et al\[[@B161]\] 2014                                                                           
  52            China            HBV: 63%, HCV: 4%                  85 (HD: 42, HV: 43)     D                       Zhuang et al\[[@B195]\] 2016                                                                       
  miR-22        Down             Serum                              192                     Egypt                   HCV: 100%                          192 (HD: 192)                  D                                Zekri et al\[[@B194]\] 2016
  miR-24-3p     Up               Serum                              84                      China                   HBV: 100%                          77 (HD: 31, HV: 46)            D, P                             Meng et al\[[@B165]\] 2014
  miR-26a       Down             Plasma                             457                     China                   HBV: 100%                          477 (HD: 310, HV: 167)         D                                Zhou et al\[[@B150]\] 2011
  Serum         52               China                              HBV: 63%, HCV: 4%       85 (HD42, HV: 43)       D                                  Zhuang et al\[[@B195]\] 2016                                    
  miR-26a-5p    Down             Serum                              261                     China                   HBV: 100%                          406 (HD 233, HV: 173)          D                                Tan et al\[[@B166]\] 2014
  miR-27a       Down             Plasma                             457                     China                   HBV: 100%                          477 (HD: 310, HV: 167)         D                                Zhou et al\[[@B150]\] 2011
  miR-29b       Down             Serum                              192                     Egypt                   HCV: 100%                          192 (HD: 192)                  D                                Zekri et al\[[@B194]\] 2016
  miR-30c       Down             Serum                              242                     China                   HCV: 63%                           NA                             P                                Liu et al\[[@B176]\] 2015
  miR-30c-5p    Down             Serum                              8                       Turkey                  HCV: 100%                          84 (HD: 56, HV: 28)            D                                Oksuz et al\[[@B178]\] 2015
  miR-34a       Up               Serum                              112                     Egypt                   HCV: 100%                          167 (HD: 125, HV: 42)          D                                Motawi et al\[[@B177]\] 2015
  miR-92a-3p    Up               Plasma                             20                      Turkey                  HBV: 100%                          74 (HD: 46, HV: 28)            D                                Giray et al\[[@B162]\] 2014
  miR-96        Up               Serum                              104                     China                   HBV: 100%                          400 (HD: 280, HV: 120)         D                                Chen et al\[[@B171]\] 2015
  miR-101       Up               Serum                              25                      China                   HBV: 100%                          20 (HV: 20)                    D                                Fu et al\[[@B154]\] 2013
  Down          Serum            67                                 China                   HBV: 100%               170 (HD: 140, HV: 3,)              D                              Xie et al\[[@B167]\] 2014        
  20            South Korea      HBV: 70%                           40 (HD: 40)             D                       Sohn et al\[[@B179]\] 2015                                                                         
  52            China            HBV: 63%, HCV: 4%                  85 (HD: 42, HV: 43)     D                       Zhuang et al\[[@B195]\] 2016                                                                       
  miR-106b      Up               Blood                              27                      China                   Alcohol: 23%                       81 (HD: 31, HV: 50,)           D                                Jiang et al\[[@B175]\] 2015
  miR-122       Up               Serum                              70                      China                   HBV: 100%                          72 (HD: 48, HV: 24,)           D                                Qi et al\[[@B147]\] 2011
  101           China            HBV: 75%                           137 (HD: 48, HV: 89,)   D                       Xu et al\[[@B149]\] 2011                                                                           
  195           Germany          HCV: 45%, Alcohol: 33%, HBV: 17%   54 (HD: 54)             P                       Köberle et al\[[@B155]\] 2013                                                                      
  30            Egypt            HCV: 100%                          70 (HD: 60, HV: 10)     D                       El-Garem et al\[[@B160]\] 2014                                                                     
  136           China            HBV: 95%                           NA                      P                       Liu et al\[[@B164]\] 2014                                                                          
  192           Egypt            HCV: 100%                          192 (HD: 192)           D                       Zekri et al\[[@B194]\] 2016                                                                        
  Down          Plasma           457                                China                   HBV: 100%               477 (HD: 310, HV: 167)             D                              Zhou et al\[[@B150]\] 2011       
  Serum         20               South Korea                        HBV: 70%                40 (HD: 40)             D                                  Sohn et al\[[@B179]\] 2015                                      
  122           China            NA                                 NA                      P                       Xu et al\[[@B181]\] 2015                                                                           
  miR-122a      Down             Serum                              85                      China                   HBV: 88%                           HV (HV: 85)                    D                                Luo et al\[[@B156]\] 2013
  miR-122-5p    Up               Plasma                             20                      Turkey                  HBV: 100%                          74 (HD: 46, HV: 28)            D                                Giray et al\[[@B162]\] 2014
  Plasma        120              South Korea                        HBV: 100%               NA                      P                                  Cho et al\[[@B172]\] 2015                                       
  Serum         120              China                              HBV: 100%               DN: 30                  D                                  Hung et al\[[@B189]\] 2016                                      
  Down          Serum            261                                China                   HBV: 100%               406 (HD: 233, HV: 173)             D                              Tan et al\[[@B166]\] 2014        
  miR-125b      Down             Plasma                             64                      China                   HBV: 100%                          178 (HD: 122, HV: 56)          D                                Chen et al\[[@B187]\] 2016
  miR-125b-5p   Up               Plasma                             20                      Turkey                  HBV: 100%                          74 (HD: 46, HV: 28)            D                                Giray et al\[[@B162]\] 2014
  miR-126       Up               Plasma                             59                      India                   HBV: 100%                          38 (HD: 20, HV: 18)            D                                Ghosh et al\[[@B188]\] 2016
  Down          Serum            23                                 Egypt                   HCV: 100%               55 (HD: 55)                        D                              Khairy et al\[[@B190]\] 2016     
  miR-128-2     Up               Serum                              222                     China                   HBV: 87%                           NA                             P                                Zhuang et al\[[@B184]\] 2015
  miR-129       Down             Serum                              23                      Egypt                   HCV: 100%                          55 (HD: 55)                    D                                Khairy et al\[[@B190]\] 2016
  miR-130a      Up               Serum                              112                     Egypt                   HCV: 100%                          167 (HD: 125, HV: 42)          D                                Motawi et al\[[@B177]\] 2015
  miR-130b      Up               Serum                              153                     China                   HBV: 88%                           59 (HD: 29, HV: 30)            D                                Liu et al\[[@B152]\] 2012
  miR-139       Down             Plasma                             31                      China                   NA                                 31 (HD: 31)                    D, P                             Li et al\[[@B163]\] 2014
  miR-141-3p    Up               Serum                              261                     China                   HBV: 100%                          406 (HD: 233, HV: 173)         D                                Tan et al\[[@B166]\] 2014
  miR-143       Up               Serum                              95                      China                   NA                                 245 (HD: 118, HV: 127)         D                                Zhang et al\[[@B168]\] 2014
  miR-143-3p    Up               Plasma                             59                      India                   HBV: 100%                          38 (HD: 20, HV: 18)            D                                Ghosh et al\[[@B188]\] 2016
  miR-146a      Up               Serum                              112                     Egypt                   HCV: 100%                          167 (HD: 125, HV: 42)          D                                Motawi et al\[[@B177]\] 2015
  miR-150       Down             Serum                              120                     China                   HBV: 100%                          230 (HD: 110, HV: 120)         D, P                             Yu et al\[[@B183]\] 2015
  miR-155       Down             Serum                              23                      Egypt                   HCV: 100%                          55 (HD: 55)                    D                                Khairy et al\[[@B190]\] 2016
  miR-181a      Down             Blood                              27                      China                   Alcohol: 23%                       81 (HD: 31, HV: 50)            D                                Jiang et al\[[@B75]\] 2015
  miR-181b      Up               Serum                              192                     Egypt                   HCV: 100%                          192 (HD: 192)                  D                                Zekr et al\[[@B194]\] 2016
  miR-182       Up               Serum                              103                     China                   NA                                 135 (HD: 95, HV: 40)           D, P                             Chen et al\[[@B169]\] 2015
  miR-192       Up               Plasma                             457                     China                   HBV: 100%                          477 (HD: 310, HV: 167)         D                                Zhou et al\[[@B150]\] 2011
  Serum         112              Egypt                              HCV: 100%               167 (HD: 125, HV: 42)   D                                  Motawi et al\[[@B177]\] 2015                                    
  miR-192-5p    Down             Serum                              261                     China                   HBV: 100%                          406 (HD: 233, HV: 173)         D                                Tan et al\[[@B166]\] 2014
  miR-195       Down             Serum                              112                     Egypt                   HCV: 100%                          167 (HD: 125, HV: 42)          D                                Motawi et al\[[@B177]\] 2015
  20            South Korea      HBV: 70%                           40 (HD: 40)             D                       Sohn et al\[[@B179]\] 2015                                                                         
  miR-199a      Down             Serum                              105                     United States           HCV: 64%, HBV: 20%                 178 (HD: 107, HV: 71)          D                                Qu et al\[[@B148]\] 2011
  40            Egypt            HCV: 100%                          60 (HD: 40, HV: 20)     D, P                    El-Abd et al\[[@B174]\] 2015                                                                       
  78            China            NA                                 156 (HV: 156)           D                       Yin et al\[[@B182]\] 2015                                                                          
  23            Egypt            HCV: 87%, HBV: 13%                 17 (HD: 17)             D                       Amr et al\[[@B186]\] 2016                                                                          
  miR-199a-3p   Down             Serum                              192                     Egypt                   HCV: 100%                          192 (HD: 192)                  D                                Zekri et al\[[@B194]\] 2016
  miR-199a-5p   Down             Serum                              261                     China                   HBV: 100%                          406 (HD: 233, HV: 173)         D                                Tan et al\[[@B166]\] 2014
  miR-200a      Up               Serum                              136                     China                   HBV: 95%                           NA                             P                                Liu et al\[[@B176]\] 2015
  miR-203       Down             Serum                              23                      Egypt                   HCV: 100%                          55 (HD: 55)                    D                                Khairy et al\[[@B190]\] 2016
  miR-203a      Down             Serum                              242                     China                   HCV: 63%                           NA                             P                                Liu et al\[[@B176]\] 2015
  miR-206       Up               Serum                              261                     China                   HBV: 100%                          406 (HD: 233, HV: 173)         D                                Tan et al\[[@B166]\] 2014
  miR-215       Up               Serum                              95                      China                   NA                                 245 (HD: 118, HV: 127)         D                                Zhang et al\[[@B168]\] 2014
  miR-218       Down             Serum                              156                     China                   HBV: 72%                           162 (HD: 98, HV: 64)           D, P                             Yang et al\[[@B193]\] 2016
  miR-221       Up               Serum                              20                      South Korea             HBV: 70%                           40 (HD: 40)                    D                                Sohn et al\[[@B179]\] 2015
  192           Egypt            HCV: 100%                          192 (HD: 192)           D                       Zekri et al\[[@B194]\] 2016                                                                        
  Down          Serum            30                                 Egypt                   HCV: 100%               70 (HD: 60, HV: 10)                D                              El-Garem et al\[[@B174]\] 2014   
  miR-222       Up               Serum                              70                      China                   HBV: 100%                          72 (HD: 48, HV: 24)            D                                Qi et al\[[@B147]\] 2011
  20            South Korea      HBV: 70%                           40 (HD: 40)             D                       Sohn et al\[[@B179]\] 2015                                                                         
  miR-223       Up               Serum                              70                      China                   HBV: 100%                          72 (HD: 48, HV: 24)                                             Qi et al\[[@B147]\] 2011
  Serum         101              China                              HBV: 75%                137 (HD: 48, HV: 89)    D                                  Xu et al\[[@B149]\] 2011                                        
  Down          Plasma           457                                China                   HBV: 100%               477 (HD: 310, HV: 167)             D                              Zhou et al\[[@B150]\] 2011       
  Serum         23               Egypt                              HCV: 100%               55 (HD: 55)             D                                  Khairy et al\[[@B190]\] 2016                                    
  miR-223-3p    Down             Plasma                             20                      Turkey                  HBV: 100%                          74 (HD: 46, HV: 28)            D                                Giray et al\[[@B162]\] 2014
  Serum         8                Turkey                             HCV: 100%               84 (HD: 56, HV: 28)     D                                  Oksuz et al\[[@B178]\] 2015                                     
  miR-224       Up               Plasma                             107                     Japan                   HCV: 41%, HBV: 18%, Alcohol: 15%   102 (HD: 27, HV: 75)           D, P, T                          Okajima et al\[[@B192]\] 2016
  Serum         20               South Korea                        HBV: 70%                40 (HD: 40)             D                                  Sohn et al\[[@B179]\] 2015                                      
  182           China            HBV: 87%                           NA                      D, P                    Zhuang et al\[[@B185]\] 2015                                                                       
  122           China            HBV: 100%                          157 (HD: 135, HV: 22)   D                       Lin et al\[[@B191]\] 2016                                                                          
  miR-224-5p    Up               Serum                              136                     China                   HBV: 95%                           NA                             P                                Liu et al\[[@B164]\] 2014
  miR-296       Up               Serum                              112                     Egypt                   HCV: 100%                          167 (HD: 125, HV: 42)          D                                Motawi et al\[[@B177]\] 2015
  miR-302c-3p   Down             Serum                              8                       Turkey                  HCV: 100%                          84 (HD: 56, HV: 28,)           D                                Oksuz et al\[[@B178]\] 2015
  miR-331-3p    Up               Serum                              103                     China                   NA                                 135 (HD: 95, HV: 40)           D, P                             Chen et al\[[@B169]\] 2015
  miR-335       Down             Serum                              125                     China                   NA                                 250 (HD: 125, HV: 125)         D, P                             Cui et al\[[@B173]\] 2015
  miR-338-5p    Up               Plasma                             37                      China                   NA                                 60 (HD: 29, HV: 31)            D                                Chen et al\[[@B170]\] 2015
  miR-375       Up               Serum                              120                     China                   HBV: 100%                          393 (HD: 183, HV: 210)         D                                Li et al\[[@B145]\] 2010,
  Down          78               China                              NA                      156 (HV: 156)           D                                  Yin et al\[[@B182]\] 2015.                                      
  miR-433-3p    Up               Serum                              261                     China                   HBV: 100%                          406 (HD: 233, HV: 173)         D                                Tan et al\[[@B166]\] 2014
  miR-483-5p    Up               Serum                              69                      United States           HCV: 63%, HBV: 14%                 69 (HV: 69)                    D                                Shen et al\[[@B157]\] 2013
  112           China            NA                                 141 (HD: 56, HV: 85)    D                       Zhang et al\[[@B158]\] 2013                                                                        
  miR-500a      Up               Serum                              112                     China                   NA                                 141 (HD: 56, HV: 85)           D                                Zhang et al\[[@B158]\] 2013
  miR-764       Up               Plasma                             37                      China                   NA                                 60 (HD: 29, HV: 31)            D                                Chen et al\[[@B170]\] 2015
  miR-801       Up               Plasma                             457                     China                   HBV: 100%                          477 (HD: 310, HV: 167)         D                                Zhou et al\[[@B150]\] 2011
  miR-885-5p    Up               Serum                              46                      China                   HBV: 72%                           105 (HD: 64, HV: 24, GC: 17)   D                                Gui et al\[[@B146]\] 2011
  192           Egypt            HCV: 100%                          192 (HD: 192)           D                       Zekri et al\[[@B194]\] 2016                                                                        
  miR-1228-5p   Up               Serum                              261                     China                   HBV: 100%                          406 (HD: 233, HV: 173)         D                                Tan et al\[[@B166]\] 2014
  let-7b        Up               Serum                              120                     China                   HBV: 100%                          30 (DN: 30)                    D                                Hung et al\[[@B189]\] 2016
  let-7f        Down             Serum                              90                      China                   NA                                 60 (HV: 60)                    D, P                             Ge et al\[[@B161]\] 2014

NA: Not applicable; HV: Healthy volunteers; HD: Hepatic disease without evidence of HCC; GC: Gastric cancer; DN: Dysplastic nodule; D: Diagnostic marker; P: Prognostic marker; T: Treatment outcome marker.

In terms of diagnosis, it should fully consider that HCC is an extremely prominent cancer among high-risk group patients. Patients who are already infected with HBV and HCV, and/or liver cirrhosis are at risk of developing liver cancer; however, some candidate miRNAs could not discriminate HCC patients from patients with liver chronic hepatitis, or cirrhosis\[[@B146],[@B147],[@B149],[@B160],[@B162],[@B179],[@B187]\]. They were useful for detecting HCC from general population, but not suitable for further screening, narrowing down patients who already have some risks for HCC. Recently, Zhou et al\[[@B150]\], Okusuz et al\[[@B178]\], Lin et al\[[@B191]\], and Zekri et al\[[@B194]\] defined three subgroups of healthy volunteers, with patients with chronic hepatitis and cirrhosis as controls. Most recently, Motawi et al\[[@B177]\] and our group\[[@B192]\] set subgroups according to fibrosis stage. To demonstrate the clinical utility for diagnosis, it is necessary to select appropriate controls.

Accumulating evidence of circulating cell-free miRNAs made clear their clinical utility as prognostic biomarker as well as a marker for the detection of HCC\[[@B184],[@B196]-[@B205]\]. In terms of the two types of curative treatment, Zheng et al\[[@B159]\] demonstrated that the level of serum miR-17-5p could serve as a novel prognostic marker for HCC patients who underwent surgical resection, and Cho et al\[[@B172]\] demonstrated that high plasma miR-122 expression was associated with poor overall survival in patients with HBV-related HCC who underwent radiofrequency ablation (RFA). In terms of the treatment for unresectable HCC, trans-arterial chemoembolization (TACE), Liu et al\[[@B164]\] demonstrated that miR-200a was the independent prognostic factor associated with survival.

Most recently, our group found that miR-224 may be an indicator of residual tumor in non-surgical treatment, such as percutaneous ablation therapy and/or TACE, although this was preliminary result because the number of cases was small\[[@B192]\]. Despite accumulating evidence, we should recognize that several challenges remain for clinical application. Regarding inter- and intra-individual variation, the kind of blood samples such as serum, plasma or all blood for better clinical application of miRNAs as a liquid-based biomarker, many issues should be addressed. Furthermore, it is necessary to build a consensus what molecule is suitable for clinical application.

Recent research has demonstrated that several noncoding RNAs regulate oncogenic and/or tumor-suppressive functions. PTEN\[[@B150],[@B180]\], Stathmin1\[[@B150]\], RUNX3\[[@B152]\], Rho-kinase 2\[[@B164]\], Mcl-1\[[@B167]\], SOX9\[[@B167]\], p21/E2F5\[[@B175]\], FNDC3B\[[@B168]\], VEGF\[[@B177]\], TP53INP1\[[@B169]\], LIN28B\[[@B187]\], ADAM17\[[@B194]\], ISRE\[[@B194]\], CDKN1B/p27\[[@B194]\], CDKN1C/p57\[[@B194]\], TIMP3\[[@B194]\], HDAC4\[[@B194]\], and mTOR\[[@B194]\], have been demonstrated to have cancer-related functions, and validated as targets for specific miRNAs in the blood of patients with HCC\[[@B206]\]. The noncoding RNAs, such as lncRNA, snoRNA, snRNA, and piRNA, in the blood of patients with HCC remain unexplored. We hope further studies of circulating noncoding RNAs based on the knowledge of recent years in HCC will shed more light on this research field.

CONCLUSION
==========

Blood-based molecular biomarkers, the most typical one of the so-called liquid biopsy, are promising as diagnostic, therapeutic and/or prognostic markers for HCC because researchers has got over their clinical difficulties such as anatomical reasons, invasive nature, and/or the patient's poor hepatic status. Although the clinical utility of liquid biopsy in HCC has been practically guaranteed by many research groups, there remains large variance in the results. The lack of a standardized technical approach has contributed to the lack of consensus. The techniques adopted, patient's hepatic status, sample type, storage conditions and target molecules have differed according to study groups. Thus, large-scale study, which is performed in a uniform methodology through all processes, is required. Another important reason is the etiological difference in each cohort. HCC is a marked regional clustering cancer, the background liver is different for each study group. For example, as indicated in each of the Tables, while all patients were infected with HBV in some reports from China and South Korea, all patients infected with HCV in other reports from Egypt. Their results were too biased by sample characteristics, it is desirable to be validated in another cohort before further clinical application.

The utility of the current serum biomarkers, such as AFP, AFP-L3, and proteins induced through vitamin K deficiency, and imaging modalities, such as ultrasonography, computed tomography, and gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced liver magnetic resonance imaging (GdEOB-DTPA-enhanced MRI) is far from satisfactory. What is now required is less invasive and repeatable methodology. Accumulating evidence of liquid biopsy might facilitate a more sensitive diagnosis and individualized decision-making in the duration of treatment of HCC. A challenge is how to achieve further development based on recent studies. Many issues should be addressed before these promising results can be translated into a real clinical settings.
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